Enlivex 1-for-15 Reverse Stock Split
Analysis based on 7 articles · First reported Jul 07, 2026 · Last updated Jul 07, 2026
The reverse split aims to boost the stock price to meet Nasdaq listing requirements, but the market reacted negatively with a pre-market decline. The reduced share count may attract institutional investors, but the company's fundamentals remain unchanged.
Enlivex Therapeutics Ltd., a clinical-stage immunotherapy company, announced a 1-for-15 reverse stock split of its ordinary shares, effective July 9, 2026. The split consolidates every 15 shares into one, reducing outstanding shares from 252.5 million to approximately 16.8 million and authorized shares from 2.375 billion to 158.3 million. The par value increases from NIS 0.40 to NIS 6.00. Fractional shares will be rounded up, and adjustments will be made to warrants and options. The stock trades on Nasdaq under ENLV. Pre-market trading saw the stock decline, reflecting negative sentiment.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard